Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Insurance coverage for weight-loss drugs has recently increased, but typically only covers branded versions, according to ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

W. Timothy Garvey, M.D., served as lead author in the clinical trial. A new combination drug therapy is showing extraordinary ...

Eli Lilly bets on next-generation obesity candidates like orforglipron and retatrutide to sustain growth amid rising ...

Shares in Danish pharmaceuticals giant Novo Nordisk (NOVO-B.CO, NVO) have continued to come under pressure amid competition in the weight-loss drug space, while UK health officials have launched a ...